#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Discussion
1-1	0-2	3.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=The statistical analysis of the collected data at each visit shows a very good trend for hydrogel containing trehalose and ceramides based ingredient at each visit :
2-1	14-17	The	abstract[2]	new[2]	_	_
2-2	18-29	statistical	abstract[2]	new[2]	_	_
2-3	30-38	analysis	abstract[2]	new[2]	_	_
2-4	39-41	of	abstract[2]	new[2]	_	_
2-5	42-45	the	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-6	46-55	collected	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-7	56-60	data	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-8	61-63	at	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-9	64-68	each	abstract[2]|abstract[3]|event[4]	new[2]|new[3]|new[4]	coref	2-25[10_4]
2-10	69-74	visit	abstract[2]|abstract[3]|event[4]	new[2]|new[3]|new[4]	_	_
2-11	75-80	shows	_	_	_	_
2-12	81-82	a	abstract[5]	new[5]	_	_
2-13	83-87	very	abstract[5]	new[5]	_	_
2-14	88-92	good	abstract[5]	new[5]	_	_
2-15	93-98	trend	abstract[5]	new[5]	_	_
2-16	99-102	for	abstract[5]	new[5]	_	_
2-17	103-111	hydrogel	abstract[5]|substance	new[5]|new	coref	4-22[25_0]
2-18	112-122	containing	_	_	_	_
2-19	123-132	trehalose	substance	new	coref	4-21
2-20	133-136	and	_	_	_	_
2-21	137-146	ceramides	substance	new	coref	4-19[21_0]
2-22	147-152	based	substance[9]	new[9]	coref	4-23[0_9]
2-23	153-163	ingredient	substance[9]	new[9]	_	_
2-24	164-166	at	substance[9]	new[9]	_	_
2-25	167-171	each	substance[9]|event[10]	new[9]|giv[10]	coref	7-25[47_10]
2-26	172-177	visit	substance[9]|event[10]	new[9]|giv[10]	_	_
2-27	178-179	:	_	_	_	_

#Text=Evaporimetry ( Transepidermal Water Loss ( TEWL ) )
3-1	180-192	Evaporimetry	substance	new	coref	4-1
3-2	193-194	(	_	_	_	_
3-3	195-209	Transepidermal	person[12]	new[12]	coref	41-1[306_12]
3-4	210-215	Water	person[12]	new[12]	_	_
3-5	216-220	Loss	person[12]	new[12]	_	_
3-6	221-222	(	person[12]	new[12]	_	_
3-7	223-227	TEWL	person[12]|abstract	new[12]|new	coref	11-8
3-8	228-229	)	person[12]	new[12]	_	_
3-9	230-231	)	_	_	_	_

#Text=Evaporimetry was used to detect any influence on the water barrier function of the skin following application of ceramides and trehalose based ingredient hydrogel and placebo hydrogel .
4-1	232-244	Evaporimetry	abstract	giv	coref	8-14
4-2	245-248	was	_	_	_	_
4-3	249-253	used	_	_	_	_
4-4	254-256	to	_	_	_	_
4-5	257-263	detect	_	_	_	_
4-6	264-267	any	abstract[15]	new[15]	_	_
4-7	268-277	influence	abstract[15]	new[15]	_	_
4-8	278-280	on	abstract[15]	new[15]	_	_
4-9	281-284	the	abstract[15]|abstract[18]	new[15]|new[18]	_	_
4-10	285-290	water	abstract[15]|substance|abstract[18]	new[15]|new|new[18]	coref	6-8
4-11	291-298	barrier	abstract[15]|object|abstract[18]	new[15]|new|new[18]	coref	6-17
4-12	299-307	function	abstract[15]|abstract[18]	new[15]|new[18]	_	_
4-13	308-310	of	abstract[15]|abstract[18]	new[15]|new[18]	_	_
4-14	311-314	the	abstract[15]|abstract[18]|object[19]	new[15]|new[18]|new[19]	coref	6-16[0_19]
4-15	315-319	skin	abstract[15]|abstract[18]|object[19]	new[15]|new[18]|new[19]	_	_
4-16	320-329	following	_	_	_	_
4-17	330-341	application	abstract[20]	new[20]	coref	10-3[0_20]
4-18	342-344	of	abstract[20]	new[20]	_	_
4-19	345-354	ceramides	abstract[20]|substance[21]	new[20]|giv[21]	coref	7-9[39_21]
4-20	355-358	and	abstract[20]|substance[21]	new[20]|giv[21]	_	_
4-21	359-368	trehalose	abstract[20]|substance[21]|substance	new[20]|giv[21]|giv	coref	7-11
4-22	369-374	based	abstract[20]|substance[21]|substance[25]	new[20]|giv[21]|giv[25]	coref	7-7[0_25]
4-23	375-385	ingredient	abstract[20]|substance[21]|substance|substance[25]	new[20]|giv[21]|giv|giv[25]	coref	7-13
4-24	386-394	hydrogel	abstract[20]|substance[21]|substance[25]	new[20]|giv[21]|giv[25]	_	_
4-25	395-398	and	abstract[20]|substance[21]|substance[25]	new[20]|giv[21]|giv[25]	_	_
4-26	399-406	placebo	abstract[20]|substance[21]|person|substance[25]	new[20]|giv[21]|new|giv[25]	coref	7-15
4-27	407-415	hydrogel	abstract[20]|substance[21]|substance[25]	new[20]|giv[21]|giv[25]	_	_
4-28	416-417	.	_	_	_	_

#Text=Corneometry ( Hydration )
5-1	418-429	Corneometry	substance	new	appos	5-3
5-2	430-431	(	_	_	_	_
5-3	432-441	Hydration	substance	giv	coref	6-20
5-4	442-443	)	_	_	_	_

#Text=In order to measure the amount of water present in the stratum corneum and the skin barrier condition , hydration has been evaluated through Corneometry .
6-1	444-446	In	_	_	_	_
6-2	447-452	order	_	_	_	_
6-3	453-455	to	_	_	_	_
6-4	456-463	measure	_	_	_	_
6-5	464-467	the	abstract[28]	new[28]	coref	20-19[130_28]
6-6	468-474	amount	abstract[28]	new[28]	_	_
6-7	475-477	of	abstract[28]	new[28]	_	_
6-8	478-483	water	abstract[28]|substance	new[28]|giv	coref	11-5
6-9	484-491	present	abstract[28]	new[28]	_	_
6-10	492-494	in	abstract[28]	new[28]	_	_
6-11	495-498	the	abstract[28]|place[31]	new[28]|new[31]	_	_
6-12	499-506	stratum	abstract[28]|abstract|place[31]	new[28]|new|new[31]	_	_
6-13	507-514	corneum	abstract[28]|place[31]	new[28]|new[31]	_	_
6-14	515-518	and	abstract[28]	new[28]	_	_
6-15	519-522	the	abstract[28]|abstract[34]	new[28]|new[34]	_	_
6-16	523-527	skin	abstract[28]|object|abstract[34]	new[28]|giv|new[34]	coref	8-30
6-17	528-535	barrier	abstract[28]|object|abstract[34]	new[28]|giv|new[34]	_	_
6-18	536-545	condition	abstract[28]|abstract[34]	new[28]|new[34]	_	_
6-19	546-547	,	_	_	_	_
6-20	548-557	hydration	abstract	giv	coref	6-25
6-21	558-561	has	_	_	_	_
6-22	562-566	been	_	_	_	_
6-23	567-576	evaluated	_	_	_	_
6-24	577-584	through	_	_	_	_
6-25	585-596	Corneometry	abstract	giv	coref	8-12
6-26	597-598	.	_	_	_	_

#Text=Moreover , the T-test applied to hydrogel containing ceramides and trehalose based ingredient and placebo formula gave a statistically significant difference between them at each visit , always showing better results for the hydrogel containing ceramides and trehalose based ingredient .
7-1	599-607	Moreover	_	_	_	_
7-2	608-609	,	_	_	_	_
7-3	610-613	the	abstract[37]	new[37]	_	_
7-4	614-620	T-test	abstract[37]	new[37]	_	_
7-5	621-628	applied	_	_	_	_
7-6	629-631	to	_	_	_	_
7-7	632-640	hydrogel	substance	giv	coref	7-33[49_0]
7-8	641-651	containing	_	_	_	_
7-9	652-661	ceramides	substance[39]	giv[39]	coref	7-36[50_39]
7-10	662-665	and	substance[39]	giv[39]	_	_
7-11	666-675	trehalose	substance[39]|substance	giv[39]|giv	coref	7-38
7-12	676-681	based	_	_	_	_
7-13	682-692	ingredient	substance|abstract[42]	giv|new[42]	ana|coref|ana|coref	7-23[46_42]|7-38[52_0]|7-23[46_42]|7-38[52_0]
7-14	693-696	and	abstract[42]	new[42]	_	_
7-15	697-704	placebo	abstract[42]|person|object[44]	new[42]|giv|new[44]	coref|coref|coref|coref	9-22|10-6[78_44]|9-22|10-6[78_44]
7-16	705-712	formula	abstract[42]|object[44]	new[42]|new[44]	_	_
7-17	713-717	gave	_	_	_	_
7-18	718-719	a	abstract[45]	new[45]	_	_
7-19	720-733	statistically	abstract[45]	new[45]	_	_
7-20	734-745	significant	abstract[45]	new[45]	_	_
7-21	746-756	difference	abstract[45]	new[45]	_	_
7-22	757-764	between	abstract[45]	new[45]	_	_
7-23	765-769	them	abstract[45]|abstract[46]	new[45]|giv[46]	coref	25-12[181_46]
7-24	770-772	at	abstract[45]|abstract[46]	new[45]|giv[46]	_	_
7-25	773-777	each	abstract[45]|abstract[46]|event[47]	new[45]|giv[46]|giv[47]	coref	9-13[70_47]
7-26	778-783	visit	abstract[45]|abstract[46]|event[47]	new[45]|giv[46]|giv[47]	_	_
7-27	784-785	,	_	_	_	_
7-28	786-792	always	_	_	_	_
7-29	793-800	showing	_	_	_	_
7-30	801-807	better	abstract[48]	new[48]	coref	9-1[66_48]
7-31	808-815	results	abstract[48]	new[48]	_	_
7-32	816-819	for	abstract[48]	new[48]	_	_
7-33	820-823	the	abstract[48]|substance[49]	new[48]|giv[49]	_	_
7-34	824-832	hydrogel	abstract[48]|substance[49]	new[48]|giv[49]	_	_
7-35	833-843	containing	_	_	_	_
7-36	844-853	ceramides	substance[50]	giv[50]	coref	8-27[0_50]
7-37	854-857	and	substance[50]	giv[50]	_	_
7-38	858-867	trehalose	substance[50]|substance|substance[52]	giv[50]|giv|giv[52]	coref|coref|coref|coref	8-25|9-10[69_52]|8-25|9-10[69_52]
7-39	868-873	based	substance[50]|substance[52]	giv[50]|giv[52]	_	_
7-40	874-884	ingredient	substance[50]|substance[52]	giv[50]|giv[52]	_	_
7-41	885-886	.	_	_	_	_

#Text=The double-blind , placebo-controlled study was performed to assess , by corneometry and evaporimetry , the barrier normalizing efficacy of a topical product containing trehalose and ceramides to alleviate skin dryness on limbs .
8-1	887-890	The	abstract[53]	new[53]	_	_
8-2	891-903	double-blind	abstract[53]	new[53]	_	_
8-3	904-905	,	_	_	_	_
8-4	906-924	placebo-controlled	abstract[54]	new[54]	coref	9-2[0_54]
8-5	925-930	study	abstract[54]	new[54]	_	_
8-6	931-934	was	_	_	_	_
8-7	935-944	performed	_	_	_	_
8-8	945-947	to	_	_	_	_
8-9	948-954	assess	_	_	_	_
8-10	955-956	,	_	_	_	_
8-11	957-959	by	_	_	_	_
8-12	960-971	corneometry	abstract	giv	coref	14-4
8-13	972-975	and	_	_	_	_
8-14	976-988	evaporimetry	object	giv	appos	8-16[57_0]
8-15	989-990	,	_	_	_	_
8-16	991-994	the	object[57]	giv[57]	coref	17-36[104_57]
8-17	995-1002	barrier	object[57]	giv[57]	_	_
8-18	1003-1014	normalizing	_	_	_	_
8-19	1015-1023	efficacy	abstract[58]	new[58]	_	_
8-20	1024-1026	of	abstract[58]	new[58]	_	_
8-21	1027-1028	a	abstract[58]|object[59]	new[58]|new[59]	coref	25-6[177_59]
8-22	1029-1036	topical	abstract[58]|object[59]	new[58]|new[59]	_	_
8-23	1037-1044	product	abstract[58]|object[59]	new[58]|new[59]	_	_
8-24	1045-1055	containing	_	_	_	_
8-25	1056-1065	trehalose	substance	giv	coref	10-10[79_0]
8-26	1066-1069	and	_	_	_	_
8-27	1070-1079	ceramides	substance	giv	coref	10-13
8-28	1080-1082	to	_	_	_	_
8-29	1083-1092	alleviate	_	_	_	_
8-30	1093-1097	skin	object|abstract[63]	giv|new[63]	coref|coref	17-32[103_0]|17-32[103_0]
8-31	1098-1105	dryness	abstract[63]	new[63]	_	_
8-32	1106-1108	on	_	_	_	_
8-33	1109-1114	limbs	object	new	_	_
8-34	1115-1116	.	_	_	_	_

#Text=The study results show a significant moisturizing effect of the ingredient at each visit , both versus baseline and versus the placebo control ( p < 0.01 ) .
9-1	1117-1120	The	abstract[66]	giv[66]	coref	17-1[95_66]
9-2	1121-1126	study	abstract|abstract[66]	giv|giv[66]	coref	25-3[176_0]
9-3	1127-1134	results	abstract[66]	giv[66]	_	_
9-4	1135-1139	show	_	_	_	_
9-5	1140-1141	a	abstract[68]	new[68]	coref	17-5[97_68]
9-6	1142-1153	significant	abstract[68]	new[68]	_	_
9-7	1154-1166	moisturizing	object|abstract[68]	new|new[68]	coref	17-7
9-8	1167-1173	effect	abstract[68]	new[68]	_	_
9-9	1174-1176	of	abstract[68]	new[68]	_	_
9-10	1177-1180	the	abstract[68]|substance[69]	new[68]|giv[69]	coref	10-14[81_69]
9-11	1181-1191	ingredient	abstract[68]|substance[69]	new[68]|giv[69]	_	_
9-12	1192-1194	at	abstract[68]|substance[69]	new[68]|giv[69]	_	_
9-13	1195-1199	each	abstract[68]|substance[69]|event[70]	new[68]|giv[69]|giv[70]	_	_
9-14	1200-1205	visit	abstract[68]|substance[69]|event[70]	new[68]|giv[69]|giv[70]	_	_
9-15	1206-1207	,	abstract[68]	new[68]	_	_
9-16	1208-1212	both	abstract[68]|abstract[71]	new[68]|new[71]	_	_
9-17	1213-1219	versus	abstract[68]|abstract[71]	new[68]|new[71]	_	_
9-18	1220-1228	baseline	abstract[68]|abstract[71]	new[68]|new[71]	_	_
9-19	1229-1232	and	_	_	_	_
9-20	1233-1239	versus	_	_	_	_
9-21	1240-1243	the	abstract[73]	new[73]	_	_
9-22	1244-1251	placebo	person|abstract[73]	giv|new[73]	coref	21-15[147_0]
9-23	1252-1259	control	abstract[73]	new[73]	_	_
9-24	1260-1261	(	_	_	_	_
9-25	1262-1263	p	quantity	new	coref	24-17
9-26	1264-1265	<	_	_	_	_
9-27	1266-1270	0.01	quantity	new	_	_
9-28	1271-1272	)	_	_	_	_
9-29	1273-1274	.	_	_	_	_

#Text=For the application site of topical cosmetic formula containing a trehalose and ceramides based ingredient :
10-1	1275-1278	For	_	_	_	_
10-2	1279-1282	the	place[77]	new[77]	coref	26-26[205_77]
10-3	1283-1294	application	abstract|place[77]	giv|new[77]	_	_
10-4	1295-1299	site	place[77]	new[77]	_	_
10-5	1300-1302	of	place[77]	new[77]	_	_
10-6	1303-1310	topical	place[77]|object[78]	new[77]|giv[78]	_	_
10-7	1311-1319	cosmetic	place[77]|object[78]	new[77]|giv[78]	_	_
10-8	1320-1327	formula	place[77]|object[78]	new[77]|giv[78]	_	_
10-9	1328-1338	containing	_	_	_	_
10-10	1339-1340	a	substance[79]	giv[79]	coref	19-16[0_79]
10-11	1341-1350	trehalose	substance[79]	giv[79]	_	_
10-12	1351-1354	and	_	_	_	_
10-13	1355-1364	ceramides	substance	giv	coref	19-18
10-14	1365-1370	based	substance[81]	giv[81]	coref	19-19[123_81]
10-15	1371-1381	ingredient	substance[81]	giv[81]	_	_
10-16	1382-1383	:	_	_	_	_

#Text=( 1 ) Transepidermal water loss ( TEWL ) value shows a reduction of −54 % after 4 weeks (
11-1	1384-1385	(	abstract[83]	new[83]	coref	20-35[135_83]
11-2	1386-1387	1	abstract[83]	new[83]	_	_
11-3	1388-1389	)	abstract[83]	new[83]	_	_
11-4	1390-1404	Transepidermal	abstract[83]	new[83]	_	_
11-5	1405-1410	water	substance|abstract[83]	giv|new[83]	coref	17-46
11-6	1411-1415	loss	abstract[83]	new[83]	_	_
11-7	1416-1417	(	_	_	_	_
11-8	1418-1422	TEWL	abstract	giv	coref	20-41
11-9	1423-1424	)	_	_	_	_
11-10	1425-1430	value	abstract	new	coref	24-14[172_0]
11-11	1431-1436	shows	_	_	_	_
11-12	1437-1438	a	abstract[86]	new[86]	_	_
11-13	1439-1448	reduction	abstract[86]	new[86]	_	_
11-14	1449-1451	of	abstract[86]	new[86]	_	_
11-15	1452-1455	−54	abstract[86]|quantity[87]	new[86]|new[87]	coref	14-9[92_87]
11-16	1456-1457	%	abstract[86]|quantity[87]	new[86]|new[87]	_	_
11-17	1458-1463	after	_	_	_	_
11-18	1464-1465	4	time[88]	new[88]	coref	14-12[93_88]
11-19	1466-1471	weeks	time[88]	new[88]	_	_
11-20	1472-1473	(	_	_	_	_

#Text=Figure 2
12-1	1474-1480	Figure	abstract[89]	new[89]	_	_
12-2	1481-1482	2	abstract[89]	new[89]	_	_

#Text=) .
13-1	1483-1484	)	_	_	_	_
13-2	1485-1486	.	_	_	_	_

#Text=( 2 ) Hydration shows an increase of 102 % after 4 weeks (
14-1	1487-1488	(	_	_	_	_
14-2	1489-1490	2	_	_	_	_
14-3	1491-1492	)	_	_	_	_
14-4	1493-1502	Hydration	abstract	giv	coref	32-16
14-5	1503-1508	shows	_	_	_	_
14-6	1509-1511	an	abstract[91]	new[91]	_	_
14-7	1512-1520	increase	abstract[91]	new[91]	_	_
14-8	1521-1523	of	abstract[91]	new[91]	_	_
14-9	1524-1527	102	abstract[91]|quantity[92]	new[91]|giv[92]	_	_
14-10	1528-1529	%	abstract[91]|quantity[92]	new[91]|giv[92]	_	_
14-11	1530-1535	after	_	_	_	_
14-12	1536-1537	4	time[93]	giv[93]	coref	25-56[195_93]
14-13	1538-1543	weeks	time[93]	giv[93]	_	_
14-14	1544-1545	(	_	_	_	_

#Text=Figure 3
15-1	1546-1552	Figure	abstract[94]	new[94]	_	_
15-2	1553-1554	3	abstract[94]	new[94]	_	_

#Text=) .
16-1	1555-1556	)	_	_	_	_
16-2	1557-1558	.	_	_	_	_

#Text=Such results point out the significant moisturizing effect after using the cosmetic under examination and go well with the rationale of the formulation , based on ingredients able to moisturize rapidly the skin and recover the cutaneous barrier to allow it to better hold the water present into its outer layers .
17-1	1559-1563	Such	abstract[95]	giv[95]	coref	23-2[153_95]
17-2	1564-1571	results	abstract[95]	giv[95]	_	_
17-3	1572-1577	point	_	_	_	_
17-4	1578-1581	out	_	_	_	_
17-5	1582-1585	the	abstract[97]	giv[97]	_	_
17-6	1586-1597	significant	abstract[97]	giv[97]	_	_
17-7	1598-1610	moisturizing	object|abstract[97]	giv|giv[97]	_	_
17-8	1611-1617	effect	abstract[97]	giv[97]	_	_
17-9	1618-1623	after	_	_	_	_
17-10	1624-1629	using	_	_	_	_
17-11	1630-1633	the	abstract[98]	new[98]	_	_
17-12	1634-1642	cosmetic	abstract[98]	new[98]	_	_
17-13	1643-1648	under	abstract[98]	new[98]	_	_
17-14	1649-1660	examination	abstract[98]|abstract	new[98]|new	_	_
17-15	1661-1664	and	_	_	_	_
17-16	1665-1667	go	_	_	_	_
17-17	1668-1672	well	_	_	_	_
17-18	1673-1677	with	_	_	_	_
17-19	1678-1681	the	abstract[100]	new[100]	ana	17-41[0_100]
17-20	1682-1691	rationale	abstract[100]	new[100]	_	_
17-21	1692-1694	of	abstract[100]	new[100]	_	_
17-22	1695-1698	the	abstract[100]|substance[101]	new[100]|new[101]	coref	18-8[112_101]
17-23	1699-1710	formulation	abstract[100]|substance[101]	new[100]|new[101]	_	_
17-24	1711-1712	,	_	_	_	_
17-25	1713-1718	based	_	_	_	_
17-26	1719-1721	on	_	_	_	_
17-27	1722-1733	ingredients	substance	new	_	_
17-28	1734-1738	able	_	_	_	_
17-29	1739-1741	to	_	_	_	_
17-30	1742-1752	moisturize	_	_	_	_
17-31	1753-1760	rapidly	_	_	_	_
17-32	1761-1764	the	object[103]	giv[103]	coref	18-13[114_103]
17-33	1765-1769	skin	object[103]	giv[103]	_	_
17-34	1770-1773	and	_	_	_	_
17-35	1774-1781	recover	_	_	_	_
17-36	1782-1785	the	object[104]	giv[104]	coref	20-32[133_104]
17-37	1786-1795	cutaneous	object[104]	giv[104]	_	_
17-38	1796-1803	barrier	object[104]	giv[104]	_	_
17-39	1804-1806	to	_	_	_	_
17-40	1807-1812	allow	_	_	_	_
17-41	1813-1815	it	abstract	giv	ana	17-49
17-42	1816-1818	to	_	_	_	_
17-43	1819-1825	better	_	_	_	_
17-44	1826-1830	hold	_	_	_	_
17-45	1831-1834	the	_	_	_	_
17-46	1835-1840	water	substance	giv	coref	20-38
17-47	1841-1848	present	_	_	_	_
17-48	1849-1853	into	_	_	_	_
17-49	1854-1857	its	abstract|object[108]	giv|new[108]	_	_
17-50	1858-1863	outer	object[108]	new[108]	_	_
17-51	1864-1870	layers	object[108]	new[108]	_	_
17-52	1871-1872	.	_	_	_	_

#Text=In vivo evaluation of the efficacy of a formulation for atopic and very dry skin ( Xerosis ) was done .
18-1	1873-1875	In	_	_	_	_
18-2	1876-1880	vivo	event|abstract[110]	new|new[110]	_	_
18-3	1881-1891	evaluation	abstract[110]	new[110]	_	_
18-4	1892-1894	of	abstract[110]	new[110]	_	_
18-5	1895-1898	the	abstract[110]|abstract[111]	new[110]|new[111]	_	_
18-6	1899-1907	efficacy	abstract[110]|abstract[111]	new[110]|new[111]	_	_
18-7	1908-1910	of	abstract[110]|abstract[111]	new[110]|new[111]	_	_
18-8	1911-1912	a	abstract[110]|abstract[111]|substance[112]	new[110]|new[111]|giv[112]	coref	19-4[117_112]
18-9	1913-1924	formulation	abstract[110]|abstract[111]|substance[112]	new[110]|new[111]|giv[112]	_	_
18-10	1925-1928	for	abstract[110]|abstract[111]|substance[112]	new[110]|new[111]|giv[112]	_	_
18-11	1929-1935	atopic	abstract[110]|abstract[111]|substance[112]|substance	new[110]|new[111]|giv[112]|new	coref	19-8
18-12	1936-1939	and	abstract[110]|abstract[111]|substance[112]	new[110]|new[111]|giv[112]	_	_
18-13	1940-1944	very	abstract[110]|abstract[111]|substance[112]|object[114]	new[110]|new[111]|giv[112]|giv[114]	coref	25-44[192_114]
18-14	1945-1948	dry	abstract[110]|abstract[111]|substance[112]|object[114]	new[110]|new[111]|giv[112]|giv[114]	_	_
18-15	1949-1953	skin	abstract[110]|abstract[111]|substance[112]|object[114]	new[110]|new[111]|giv[112]|giv[114]	_	_
18-16	1954-1955	(	_	_	_	_
18-17	1956-1963	Xerosis	substance	new	_	_
18-18	1964-1965	)	_	_	_	_
18-19	1966-1969	was	_	_	_	_
18-20	1970-1974	done	_	_	_	_
18-21	1975-1976	.	_	_	_	_

#Text=An example of one topical formulation for atopic dermatitis ( Table 1 ) based on trehalose and ceramides based ingredient is reported below for illustrative and non-limiting purposes .
19-1	1977-1979	An	abstract[116]	new[116]	_	_
19-2	1980-1987	example	abstract[116]	new[116]	_	_
19-3	1988-1990	of	abstract[116]	new[116]	_	_
19-4	1991-1994	one	abstract[116]|substance[117]	new[116]|giv[117]	coref	21-4[143_117]
19-5	1995-2002	topical	abstract[116]|substance[117]	new[116]|giv[117]	_	_
19-6	2003-2014	formulation	abstract[116]|substance[117]	new[116]|giv[117]	_	_
19-7	2015-2018	for	abstract[116]|substance[117]	new[116]|giv[117]	_	_
19-8	2019-2025	atopic	abstract[116]|substance[117]|abstract|object[119]	new[116]|giv[117]|giv|new[119]	appos|coref|appos|coref	19-11[120_119]|25-42|19-11[120_119]|25-42
19-9	2026-2036	dermatitis	abstract[116]|substance[117]|object[119]	new[116]|giv[117]|new[119]	_	_
19-10	2037-2038	(	_	_	_	_
19-11	2039-2044	Table	object[120]	giv[120]	coref	20-23[131_120]
19-12	2045-2046	1	object[120]	giv[120]	_	_
19-13	2047-2048	)	_	_	_	_
19-14	2049-2054	based	_	_	_	_
19-15	2055-2057	on	_	_	_	_
19-16	2058-2067	trehalose	substance	giv	coref	21-9
19-17	2068-2071	and	_	_	_	_
19-18	2072-2081	ceramides	substance	giv	coref	21-11
19-19	2082-2087	based	substance[123]	giv[123]	coref	25-12[0_123]
19-20	2088-2098	ingredient	substance[123]	giv[123]	_	_
19-21	2099-2101	is	_	_	_	_
19-22	2102-2110	reported	_	_	_	_
19-23	2111-2116	below	_	_	_	_
19-24	2117-2120	for	_	_	_	_
19-25	2121-2133	illustrative	abstract[124]	new[124]	_	_
19-26	2134-2137	and	abstract[124]	new[124]	_	_
19-27	2138-2150	non-limiting	abstract[124]	new[124]	_	_
19-28	2151-2159	purposes	abstract[124]	new[124]	_	_
19-29	2160-2161	.	_	_	_	_

#Text=Purpose of the test : To provide active substances through a form that allows a prompt release and an effective amount in atopic dermatitis , characterized by a deteriorated functionality of the barrier , an increased transepidermal water loss ( TEWL ) and a significant xerosis , as well as in the case of pathologies associated with a local subcutaneous microcirculation disorder .
20-1	2162-2169	Purpose	abstract[125]	new[125]	_	_
20-2	2170-2172	of	abstract[125]	new[125]	_	_
20-3	2173-2176	the	abstract[125]|abstract[126]	new[125]|new[126]	coref	23-5[155_126]
20-4	2177-2181	test	abstract[125]|abstract[126]	new[125]|new[126]	_	_
20-5	2182-2183	:	_	_	_	_
20-6	2184-2186	To	_	_	_	_
20-7	2187-2194	provide	_	_	_	_
20-8	2195-2201	active	substance[127]	new[127]	_	_
20-9	2202-2212	substances	substance[127]	new[127]	_	_
20-10	2213-2220	through	_	_	_	_
20-11	2221-2222	a	object[128]	new[128]	_	_
20-12	2223-2227	form	object[128]	new[128]	_	_
20-13	2228-2232	that	_	_	_	_
20-14	2233-2239	allows	_	_	_	_
20-15	2240-2241	a	event[129]	new[129]	_	_
20-16	2242-2248	prompt	event[129]	new[129]	_	_
20-17	2249-2256	release	event[129]	new[129]	_	_
20-18	2257-2260	and	_	_	_	_
20-19	2261-2263	an	abstract[130]	giv[130]	_	_
20-20	2264-2273	effective	abstract[130]	giv[130]	_	_
20-21	2274-2280	amount	abstract[130]	giv[130]	_	_
20-22	2281-2283	in	abstract[130]	giv[130]	_	_
20-23	2284-2290	atopic	abstract[130]|object[131]	giv[130]|giv[131]	_	_
20-24	2291-2301	dermatitis	abstract[130]|object[131]	giv[130]|giv[131]	_	_
20-25	2302-2303	,	_	_	_	_
20-26	2304-2317	characterized	_	_	_	_
20-27	2318-2320	by	_	_	_	_
20-28	2321-2322	a	abstract[132]	new[132]	_	_
20-29	2323-2335	deteriorated	abstract[132]	new[132]	_	_
20-30	2336-2349	functionality	abstract[132]	new[132]	_	_
20-31	2350-2352	of	abstract[132]	new[132]	_	_
20-32	2353-2356	the	abstract[132]|object[133]	new[132]|giv[133]	_	_
20-33	2357-2364	barrier	abstract[132]|object[133]	new[132]|giv[133]	_	_
20-34	2365-2366	,	abstract[132]	new[132]	_	_
20-35	2367-2369	an	abstract[132]|abstract[135]	new[132]|giv[135]	coref	34-7[264_135]
20-36	2370-2379	increased	abstract[132]|abstract[135]	new[132]|giv[135]	_	_
20-37	2380-2394	transepidermal	abstract[132]|abstract[135]	new[132]|giv[135]	_	_
20-38	2395-2400	water	abstract[132]|substance|abstract[135]	new[132]|giv|giv[135]	coref	34-8
20-39	2401-2405	loss	abstract[132]|abstract[135]	new[132]|giv[135]	_	_
20-40	2406-2407	(	_	_	_	_
20-41	2408-2412	TEWL	abstract	giv	coref	32-18
20-42	2413-2414	)	_	_	_	_
20-43	2415-2418	and	_	_	_	_
20-44	2419-2420	a	abstract[137]	new[137]	coref	25-48[0_137]
20-45	2421-2432	significant	abstract[137]	new[137]	_	_
20-46	2433-2440	xerosis	abstract[137]	new[137]	_	_
20-47	2441-2442	,	abstract[137]	new[137]	_	_
20-48	2443-2445	as	abstract[137]	new[137]	_	_
20-49	2446-2450	well	abstract[137]	new[137]	_	_
20-50	2451-2453	as	abstract[137]	new[137]	_	_
20-51	2454-2456	in	abstract[137]	new[137]	_	_
20-52	2457-2460	the	abstract[137]|abstract[138]	new[137]|new[138]	_	_
20-53	2461-2465	case	abstract[137]|abstract[138]	new[137]|new[138]	_	_
20-54	2466-2468	of	abstract[137]|abstract[138]	new[137]|new[138]	_	_
20-55	2469-2480	pathologies	abstract[137]|abstract[138]|abstract	new[137]|new[138]|new	_	_
20-56	2481-2491	associated	_	_	_	_
20-57	2492-2496	with	_	_	_	_
20-58	2497-2498	a	abstract[141]	new[141]	_	_
20-59	2499-2504	local	abstract[141]	new[141]	_	_
20-60	2505-2517	subcutaneous	abstract[141]	new[141]	_	_
20-61	2518-2534	microcirculation	abstract|abstract[141]	new|new[141]	_	_
20-62	2535-2543	disorder	abstract[141]	new[141]	_	_
20-63	2544-2545	.	_	_	_	_

#Text=The efficacy of a topical cosmetic formulation containing trehalose and ceramides in comparison to a placebo has been evaluated .
21-1	2546-2549	The	abstract[142]	new[142]	_	_
21-2	2550-2558	efficacy	abstract[142]	new[142]	_	_
21-3	2559-2561	of	abstract[142]	new[142]	_	_
21-4	2562-2563	a	abstract[142]|substance[143]	new[142]|giv[143]	_	_
21-5	2564-2571	topical	abstract[142]|substance[143]	new[142]|giv[143]	_	_
21-6	2572-2580	cosmetic	abstract[142]|substance[143]	new[142]|giv[143]	_	_
21-7	2581-2592	formulation	abstract[142]|substance[143]	new[142]|giv[143]	_	_
21-8	2593-2603	containing	_	_	_	_
21-9	2604-2613	trehalose	substance	giv	coref	25-9
21-10	2614-2617	and	_	_	_	_
21-11	2618-2627	ceramides	substance	giv	coref	25-11
21-12	2628-2630	in	_	_	_	_
21-13	2631-2641	comparison	abstract[146]	new[146]	_	_
21-14	2642-2644	to	abstract[146]	new[146]	_	_
21-15	2645-2646	a	abstract[146]|person[147]	new[146]|giv[147]	coref	25-14[182_147]
21-16	2647-2654	placebo	abstract[146]|person[147]	new[146]|giv[147]	_	_
21-17	2655-2658	has	_	_	_	_
21-18	2659-2663	been	_	_	_	_
21-19	2664-2673	evaluated	_	_	_	_
21-20	2674-2675	.	_	_	_	_

#Text=Mean values , standard deviations , and variations were calculated for each set of values .
22-1	2676-2680	Mean	_	_	_	_
22-2	2681-2687	values	abstract	new	coref	22-15
22-3	2688-2689	,	_	_	_	_
22-4	2690-2698	standard	quantity[149]	new[149]	_	_
22-5	2699-2709	deviations	quantity[149]	new[149]	_	_
22-6	2710-2711	,	_	_	_	_
22-7	2712-2715	and	_	_	_	_
22-8	2716-2726	variations	abstract	new	coref	23-24[162_0]
22-9	2727-2731	were	_	_	_	_
22-10	2732-2742	calculated	_	_	_	_
22-11	2743-2746	for	_	_	_	_
22-12	2747-2751	each	abstract[151]	new[151]	_	_
22-13	2752-2755	set	abstract[151]	new[151]	_	_
22-14	2756-2758	of	abstract[151]	new[151]	_	_
22-15	2759-2765	values	abstract[151]|abstract	new[151]|giv	coref	36-6[275_0]
22-16	2766-2767	.	_	_	_	_

#Text=Following the results of normality test ( Kolmogorov – Smirnov test ) , the instrumental data ( T0 , T4 weeks ) and the variations ( T4 weeks-T0 ) were statistically compared by means of t -test for parametric and dependent data .
23-1	2768-2777	Following	_	_	_	_
23-2	2778-2781	the	abstract[153]	giv[153]	_	_
23-3	2782-2789	results	abstract[153]	giv[153]	_	_
23-4	2790-2792	of	abstract[153]	giv[153]	_	_
23-5	2793-2802	normality	abstract[153]|abstract|abstract[155]	giv[153]|new|giv[155]	appos|appos	23-10[158_155]|23-10[158_155]
23-6	2803-2807	test	abstract[153]|abstract[155]	giv[153]|giv[155]	_	_
23-7	2808-2809	(	_	_	_	_
23-8	2810-2820	Kolmogorov	person	new	_	_
23-9	2821-2822	–	_	_	_	_
23-10	2823-2830	Smirnov	person|abstract[158]	new|giv[158]	coref|coref	27-6[208_158]|27-6[208_158]
23-11	2831-2835	test	abstract[158]	giv[158]	_	_
23-12	2836-2837	)	_	_	_	_
23-13	2838-2839	,	_	_	_	_
23-14	2840-2843	the	abstract[159]	new[159]	appos	23-18[0_159]
23-15	2844-2856	instrumental	abstract[159]	new[159]	_	_
23-16	2857-2861	data	abstract[159]	new[159]	_	_
23-17	2862-2863	(	_	_	_	_
23-18	2864-2866	T0	abstract	giv	coref	23-39[167_0]
23-19	2867-2868	,	_	_	_	_
23-20	2869-2871	T4	time	new	coref	23-27
23-21	2872-2877	weeks	_	_	_	_
23-22	2878-2879	)	_	_	_	_
23-23	2880-2883	and	_	_	_	_
23-24	2884-2887	the	abstract[162]	giv[162]	_	_
23-25	2888-2898	variations	abstract[162]	giv[162]	_	_
23-26	2899-2900	(	_	_	_	_
23-27	2901-2903	T4	abstract|time[164]	giv|new[164]	_	_
23-28	2904-2912	weeks-T0	time[164]	new[164]	_	_
23-29	2913-2914	)	_	_	_	_
23-30	2915-2919	were	_	_	_	_
23-31	2920-2933	statistically	_	_	_	_
23-32	2934-2942	compared	_	_	_	_
23-33	2943-2945	by	_	_	_	_
23-34	2946-2951	means	_	_	_	_
23-35	2952-2954	of	_	_	_	_
23-36	2955-2956	t	abstract|abstract[166]	new|new[166]	_	_
23-37	2957-2962	-test	abstract[166]	new[166]	_	_
23-38	2963-2966	for	_	_	_	_
23-39	2967-2977	parametric	abstract[167]	giv[167]	coref	24-8[0_167]
23-40	2978-2981	and	abstract[167]	giv[167]	_	_
23-41	2982-2991	dependent	abstract[167]	giv[167]	_	_
23-42	2992-2996	data	abstract[167]	giv[167]	_	_
23-43	2997-2998	.	_	_	_	_

#Text=In all cases , the groups of data were considered statistically different for a probability value p < 0.05 .
24-1	2999-3001	In	_	_	_	_
24-2	3002-3005	all	object[168]	new[168]	_	_
24-3	3006-3011	cases	object[168]	new[168]	_	_
24-4	3012-3013	,	_	_	_	_
24-5	3014-3017	the	abstract[169]	new[169]	_	_
24-6	3018-3024	groups	abstract[169]	new[169]	_	_
24-7	3025-3027	of	abstract[169]	new[169]	_	_
24-8	3028-3032	data	abstract[169]|abstract	new[169]|giv	_	_
24-9	3033-3037	were	_	_	_	_
24-10	3038-3048	considered	_	_	_	_
24-11	3049-3062	statistically	_	_	_	_
24-12	3063-3072	different	_	_	_	_
24-13	3073-3076	for	_	_	_	_
24-14	3077-3078	a	abstract[172]	giv[172]	_	_
24-15	3079-3090	probability	abstract|abstract[172]	new|giv[172]	_	_
24-16	3091-3096	value	abstract[172]	giv[172]	_	_
24-17	3097-3098	p	quantity	giv	_	_
24-18	3099-3100	<	_	_	_	_
24-19	3101-3105	0.05	quantity	new	_	_
24-20	3106-3107	.	_	_	_	_

#Text=Protocol of double-blind study : the product containing trehalose and ceramides ingredient and the placebo was applied on the forearms by 20 volunteers of either sex ( 1 male and 19 females with an average age of 50 years ) with atopic and very dry skin ( xerosis ) , twice a day , for 4 weeks .
25-1	3108-3116	Protocol	abstract[175]	new[175]	_	_
25-2	3117-3119	of	abstract[175]	new[175]	_	_
25-3	3120-3132	double-blind	abstract[175]|abstract[176]	new[175]|giv[176]	coref	26-2[196_176]
25-4	3133-3138	study	abstract[175]|abstract[176]	new[175]|giv[176]	_	_
25-5	3139-3140	:	_	_	_	_
25-6	3141-3144	the	object[177]	giv[177]	coref	29-19[229_177]
25-7	3145-3152	product	object[177]	giv[177]	_	_
25-8	3153-3163	containing	_	_	_	_
25-9	3164-3173	trehalose	substance	giv	coref	28-20
25-10	3174-3177	and	_	_	_	_
25-11	3178-3187	ceramides	substance	giv	coref	28-22
25-12	3188-3198	ingredient	substance|abstract[181]	giv|giv[181]	coref|coref|coref|coref	28-23[221_0]|28-23[222_181]|28-23[221_0]|28-23[222_181]
25-13	3199-3202	and	abstract[181]	giv[181]	_	_
25-14	3203-3206	the	abstract[181]|person[182]	giv[181]|giv[182]	coref	28-26[0_182]
25-15	3207-3214	placebo	abstract[181]|person[182]	giv[181]|giv[182]	_	_
25-16	3215-3218	was	_	_	_	_
25-17	3219-3226	applied	_	_	_	_
25-18	3227-3229	on	_	_	_	_
25-19	3230-3233	the	object[183]	new[183]	coref	27-19[211_183]
25-20	3234-3242	forearms	object[183]	new[183]	_	_
25-21	3243-3245	by	_	_	_	_
25-22	3246-3248	20	person[184]	new[184]	coref	28-31[224_184]
25-23	3249-3259	volunteers	person[184]	new[184]	_	_
25-24	3260-3262	of	person[184]	new[184]	_	_
25-25	3263-3269	either	person[184]|event[185]	new[184]|new[185]	_	_
25-26	3270-3273	sex	person[184]|event[185]	new[184]|new[185]	_	_
25-27	3274-3275	(	_	_	_	_
25-28	3276-3277	1	person[186]|person[187]	new[186]|new[187]	ana|ana	26-10[0_187]|26-10[0_187]
25-29	3278-3282	male	person[186]|person[187]	new[186]|new[187]	_	_
25-30	3283-3286	and	person[187]	new[187]	_	_
25-31	3287-3289	19	person[187]|person[188]	new[187]|new[188]	_	_
25-32	3290-3297	females	person[187]|person[188]	new[187]|new[188]	_	_
25-33	3298-3302	with	person[187]|person[188]	new[187]|new[188]	_	_
25-34	3303-3305	an	person[187]|person[188]|abstract[189]	new[187]|new[188]|new[189]	_	_
25-35	3306-3313	average	person[187]|person[188]|abstract[189]	new[187]|new[188]|new[189]	_	_
25-36	3314-3317	age	person[187]|person[188]|abstract[189]	new[187]|new[188]|new[189]	_	_
25-37	3318-3320	of	person[187]|person[188]|abstract[189]	new[187]|new[188]|new[189]	_	_
25-38	3321-3323	50	person[187]|person[188]|abstract[189]|quantity[190]	new[187]|new[188]|new[189]|new[190]	_	_
25-39	3324-3329	years	person[187]|person[188]|abstract[189]|quantity[190]	new[187]|new[188]|new[189]|new[190]	_	_
25-40	3330-3331	)	_	_	_	_
25-41	3332-3336	with	_	_	_	_
25-42	3337-3343	atopic	substance	giv	_	_
25-43	3344-3347	and	_	_	_	_
25-44	3348-3352	very	object[192]	giv[192]	coref	26-15[0_192]
25-45	3353-3356	dry	object[192]	giv[192]	_	_
25-46	3357-3361	skin	object[192]	giv[192]	_	_
25-47	3362-3363	(	_	_	_	_
25-48	3364-3371	xerosis	abstract	giv	_	_
25-49	3372-3373	)	_	_	_	_
25-50	3374-3375	,	_	_	_	_
25-51	3376-3381	twice	time[194]	new[194]	_	_
25-52	3382-3383	a	time[194]	new[194]	_	_
25-53	3384-3387	day	time[194]	new[194]	_	_
25-54	3388-3389	,	time[194]	new[194]	_	_
25-55	3390-3393	for	time[194]	new[194]	_	_
25-56	3394-3395	4	time[194]|time[195]	new[194]|giv[195]	coref	34-31[270_195]
25-57	3396-3401	weeks	time[194]|time[195]	new[194]|giv[195]	_	_
25-58	3402-3403	.	_	_	_	_

#Text=During the study , subjects were instructed to wash their body using their current skin care regimen and to not apply the tested products on any other site than the prescribed ones .
26-1	3404-3410	During	_	_	_	_
26-2	3411-3414	the	abstract[196]	giv[196]	coref	30-21[0_196]
26-3	3415-3420	study	abstract[196]	giv[196]	_	_
26-4	3421-3422	,	_	_	_	_
26-5	3423-3431	subjects	abstract	new	coref	27-9[209_0]
26-6	3432-3436	were	_	_	_	_
26-7	3437-3447	instructed	_	_	_	_
26-8	3448-3450	to	_	_	_	_
26-9	3451-3455	wash	_	_	_	_
26-10	3456-3461	their	person|object[199]	giv|new[199]	ana|ana	26-13|26-13
26-11	3462-3466	body	object[199]	new[199]	_	_
26-12	3467-3472	using	_	_	_	_
26-13	3473-3478	their	person|abstract[203]	giv|new[203]	_	_
26-14	3479-3486	current	abstract[203]	new[203]	_	_
26-15	3487-3491	skin	object|abstract[203]	giv|new[203]	coref	34-4
26-16	3492-3496	care	abstract|abstract[203]	new|new[203]	_	_
26-17	3497-3504	regimen	abstract[203]	new[203]	_	_
26-18	3505-3508	and	_	_	_	_
26-19	3509-3511	to	_	_	_	_
26-20	3512-3515	not	_	_	_	_
26-21	3516-3521	apply	_	_	_	_
26-22	3522-3525	the	object[204]	new[204]	coref	27-16[210_204]
26-23	3526-3532	tested	object[204]	new[204]	_	_
26-24	3533-3541	products	object[204]	new[204]	_	_
26-25	3542-3544	on	object[204]	new[204]	_	_
26-26	3545-3548	any	object[204]|place[205]	new[204]|giv[205]	_	_
26-27	3549-3554	other	object[204]|place[205]	new[204]|giv[205]	_	_
26-28	3555-3559	site	object[204]|place[205]	new[204]|giv[205]	_	_
26-29	3560-3564	than	object[204]|place[205]	new[204]|giv[205]	_	_
26-30	3565-3568	the	object[204]|place[205]|object[206]	new[204]|giv[205]|new[206]	_	_
26-31	3569-3579	prescribed	object[204]|place[205]|object[206]	new[204]|giv[205]|new[206]	_	_
26-32	3580-3584	ones	object[204]|place[205]|object[206]	new[204]|giv[205]|new[206]	_	_
26-33	3585-3586	.	_	_	_	_

#Text=For the whole duration of the test , the subjects were not allowed to use different products on the forearms and instructed to avoid UV exposure .
27-1	3587-3590	For	_	_	_	_
27-2	3591-3594	the	time[207]	new[207]	_	_
27-3	3595-3600	whole	time[207]	new[207]	_	_
27-4	3601-3609	duration	time[207]	new[207]	_	_
27-5	3610-3612	of	time[207]	new[207]	_	_
27-6	3613-3616	the	time[207]|abstract[208]	new[207]|giv[208]	_	_
27-7	3617-3621	test	time[207]|abstract[208]	new[207]|giv[208]	_	_
27-8	3622-3623	,	_	_	_	_
27-9	3624-3627	the	abstract[209]	giv[209]	coref	31-6[240_209]
27-10	3628-3636	subjects	abstract[209]	giv[209]	_	_
27-11	3637-3641	were	_	_	_	_
27-12	3642-3645	not	_	_	_	_
27-13	3646-3653	allowed	_	_	_	_
27-14	3654-3656	to	_	_	_	_
27-15	3657-3660	use	_	_	_	_
27-16	3661-3670	different	object[210]	giv[210]	coref	31-1[239_210]
27-17	3671-3679	products	object[210]	giv[210]	_	_
27-18	3680-3682	on	object[210]	giv[210]	_	_
27-19	3683-3686	the	object[210]|object[211]	giv[210]|giv[211]	coref	34-24[268_211]
27-20	3687-3695	forearms	object[210]|object[211]	giv[210]|giv[211]	_	_
27-21	3696-3699	and	_	_	_	_
27-22	3700-3710	instructed	_	_	_	_
27-23	3711-3713	to	_	_	_	_
27-24	3714-3719	avoid	_	_	_	_
27-25	3720-3722	UV	abstract|abstract[213]	new|new[213]	_	_
27-26	3723-3731	exposure	abstract[213]	new[213]	_	_
27-27	3732-3733	.	_	_	_	_

#Text=Furthermore , the side of application ( left or right forearm ) of the two formulations ( cream containing trehalose and ceramides based ingredient and placebo ) were randomized among the volunteers .
28-1	3734-3745	Furthermore	_	_	_	_
28-2	3746-3747	,	_	_	_	_
28-3	3748-3751	the	abstract[214]	new[214]	_	_
28-4	3752-3756	side	abstract[214]	new[214]	_	_
28-5	3757-3759	of	abstract[214]	new[214]	_	_
28-6	3760-3771	application	abstract[214]|abstract[215]	new[214]|new[215]	_	_
28-7	3772-3773	(	abstract[214]|abstract[215]	new[214]|new[215]	_	_
28-8	3774-3778	left	abstract[214]|abstract[215]	new[214]|new[215]	_	_
28-9	3779-3781	or	abstract[214]|abstract[215]	new[214]|new[215]	_	_
28-10	3782-3787	right	abstract[214]|abstract[215]|object[216]	new[214]|new[215]|new[216]	_	_
28-11	3788-3795	forearm	abstract[214]|abstract[215]|object[216]	new[214]|new[215]|new[216]	_	_
28-12	3796-3797	)	abstract[214]|abstract[215]	new[214]|new[215]	_	_
28-13	3798-3800	of	abstract[214]|abstract[215]	new[214]|new[215]	_	_
28-14	3801-3804	the	abstract[214]|abstract[215]|substance[217]	new[214]|new[215]|new[217]	appos	28-18[0_217]
28-15	3805-3808	two	abstract[214]|abstract[215]|substance[217]	new[214]|new[215]|new[217]	_	_
28-16	3809-3821	formulations	abstract[214]|abstract[215]|substance[217]	new[214]|new[215]|new[217]	_	_
28-17	3822-3823	(	_	_	_	_
28-18	3824-3829	cream	substance	giv	coref	37-9[293_0]
28-19	3830-3840	containing	_	_	_	_
28-20	3841-3850	trehalose	substance	giv	coref	36-25
28-21	3851-3854	and	_	_	_	_
28-22	3855-3864	ceramides	substance	giv	coref	37-6[289_0]
28-23	3865-3870	based	substance[221]|abstract[222]	giv[221]|giv[222]	coref|coref|coref|coref	32-8[246_221]|32-8[247_222]|32-8[246_221]|32-8[247_222]
28-24	3871-3881	ingredient	substance[221]|abstract[222]	giv[221]|giv[222]	_	_
28-25	3882-3885	and	abstract[222]	giv[222]	_	_
28-26	3886-3893	placebo	abstract[222]|person	giv[222]|giv	coref	32-11[248_0]
28-27	3894-3895	)	_	_	_	_
28-28	3896-3900	were	_	_	_	_
28-29	3901-3911	randomized	_	_	_	_
28-30	3912-3917	among	_	_	_	_
28-31	3918-3921	the	person[224]	giv[224]	_	_
28-32	3922-3932	volunteers	person[224]	giv[224]	_	_
28-33	3933-3934	.	_	_	_	_

#Text=Each sample was labeled “ right ” or “ left ” , indicating the side of application of the product .
29-1	3935-3939	Each	object[225]	new[225]	_	_
29-2	3940-3946	sample	object[225]	new[225]	_	_
29-3	3947-3950	was	_	_	_	_
29-4	3951-3958	labeled	_	_	_	_
29-5	3959-3960	“	_	_	_	_
29-6	3961-3966	right	abstract	new	_	_
29-7	3967-3968	”	_	_	_	_
29-8	3969-3971	or	_	_	_	_
29-9	3972-3973	“	_	_	_	_
29-10	3974-3978	left	_	_	_	_
29-11	3979-3980	”	_	_	_	_
29-12	3981-3982	,	_	_	_	_
29-13	3983-3993	indicating	_	_	_	_
29-14	3994-3997	the	abstract[227]	new[227]	_	_
29-15	3998-4002	side	abstract[227]	new[227]	_	_
29-16	4003-4005	of	abstract[227]	new[227]	_	_
29-17	4006-4017	application	abstract[227]|abstract[228]	new[227]|new[228]	_	_
29-18	4018-4020	of	abstract[227]|abstract[228]	new[227]|new[228]	_	_
29-19	4021-4024	the	abstract[227]|abstract[228]|object[229]	new[227]|new[228]|giv[229]	coref	36-30[285_229]
29-20	4025-4032	product	abstract[227]|abstract[228]|object[229]	new[227]|new[228]|giv[229]	_	_
29-21	4033-4034	.	_	_	_	_

#Text=The assignment of subject number and subsequent placement on the randomization chart were made in order of appearance at the study center on the first day .
30-1	4035-4038	The	abstract[230]	new[230]	_	_
30-2	4039-4049	assignment	abstract[230]	new[230]	_	_
30-3	4050-4052	of	abstract[230]	new[230]	_	_
30-4	4053-4060	subject	abstract[230]|abstract[231]	new[230]|new[231]	_	_
30-5	4061-4067	number	abstract[230]|abstract[231]	new[230]|new[231]	_	_
30-6	4068-4071	and	abstract[230]	new[230]	_	_
30-7	4072-4082	subsequent	abstract[230]|abstract[232]	new[230]|new[232]	_	_
30-8	4083-4092	placement	abstract[230]|abstract[232]	new[230]|new[232]	_	_
30-9	4093-4095	on	abstract[230]|abstract[232]	new[230]|new[232]	_	_
30-10	4096-4099	the	abstract[230]|abstract[232]|object[234]	new[230]|new[232]|new[234]	_	_
30-11	4100-4113	randomization	abstract[230]|abstract[232]|abstract|object[234]	new[230]|new[232]|new|new[234]	_	_
30-12	4114-4119	chart	abstract[230]|abstract[232]|object[234]	new[230]|new[232]|new[234]	_	_
30-13	4120-4124	were	_	_	_	_
30-14	4125-4129	made	_	_	_	_
30-15	4130-4132	in	_	_	_	_
30-16	4133-4138	order	_	_	_	_
30-17	4139-4141	of	_	_	_	_
30-18	4142-4152	appearance	event	new	_	_
30-19	4153-4155	at	_	_	_	_
30-20	4156-4159	the	place[237]	new[237]	_	_
30-21	4160-4165	study	abstract|place[237]	giv|new[237]	_	_
30-22	4166-4172	center	place[237]	new[237]	_	_
30-23	4173-4175	on	place[237]	new[237]	_	_
30-24	4176-4179	the	place[237]|time[238]	new[237]|new[238]	_	_
30-25	4180-4185	first	place[237]|time[238]	new[237]|new[238]	_	_
30-26	4186-4189	day	place[237]|time[238]	new[237]|new[238]	_	_
30-27	4190-4191	.	_	_	_	_

#Text=The products were given to the subjects in anonymous containers which did not provide any information about the treatment .
31-1	4192-4195	The	object[239]	giv[239]	_	_
31-2	4196-4204	products	object[239]	giv[239]	_	_
31-3	4205-4209	were	_	_	_	_
31-4	4210-4215	given	_	_	_	_
31-5	4216-4218	to	_	_	_	_
31-6	4219-4222	the	abstract[240]	giv[240]	_	_
31-7	4223-4231	subjects	abstract[240]	giv[240]	_	_
31-8	4232-4234	in	abstract[240]	giv[240]	_	_
31-9	4235-4244	anonymous	abstract[240]|object[241]	giv[240]|new[241]	_	_
31-10	4245-4255	containers	abstract[240]|object[241]	giv[240]|new[241]	_	_
31-11	4256-4261	which	_	_	_	_
31-12	4262-4265	did	_	_	_	_
31-13	4266-4269	not	_	_	_	_
31-14	4270-4277	provide	_	_	_	_
31-15	4278-4281	any	abstract[242]	new[242]	_	_
31-16	4282-4293	information	abstract[242]	new[242]	_	_
31-17	4294-4299	about	abstract[242]	new[242]	_	_
31-18	4300-4303	the	abstract[242]|event[243]	new[242]|new[243]	ana	33-1[0_243]
31-19	4304-4313	treatment	abstract[242]|event[243]	new[242]|new[243]	_	_
31-20	4314-4315	.	_	_	_	_

#Text=The comparisons evidenced statistically significant differences between studied ingredient and placebo for both parameters ( hydration and TEWL ) .
32-1	4316-4319	The	abstract[244]	new[244]	_	_
32-2	4320-4331	comparisons	abstract[244]	new[244]	_	_
32-3	4332-4341	evidenced	_	_	_	_
32-4	4342-4355	statistically	abstract[245]	new[245]	_	_
32-5	4356-4367	significant	abstract[245]	new[245]	_	_
32-6	4368-4379	differences	abstract[245]	new[245]	_	_
32-7	4380-4387	between	abstract[245]	new[245]	_	_
32-8	4388-4395	studied	abstract[245]|substance[246]|abstract[247]	new[245]|giv[246]|giv[247]	coref|coref	36-27[0_246]|36-27[0_246]
32-9	4396-4406	ingredient	abstract[245]|substance[246]|abstract[247]	new[245]|giv[246]|giv[247]	_	_
32-10	4407-4410	and	abstract[245]|abstract[247]	new[245]|giv[247]	_	_
32-11	4411-4418	placebo	abstract[245]|abstract[247]|person[248]	new[245]|giv[247]|giv[248]	coref	33-20[0_248]
32-12	4419-4422	for	abstract[245]|abstract[247]|person[248]	new[245]|giv[247]|giv[248]	_	_
32-13	4423-4427	both	abstract[245]|abstract[247]|person[248]|abstract[249]	new[245]|giv[247]|giv[248]|new[249]	_	_
32-14	4428-4438	parameters	abstract[245]|abstract[247]|person[248]|abstract[249]	new[245]|giv[247]|giv[248]|new[249]	_	_
32-15	4439-4440	(	_	_	_	_
32-16	4441-4450	hydration	substance|abstract[251]	giv|new[251]	coref|coref|coref|coref	34-4[261_0]|34-4[262_251]|34-4[261_0]|34-4[262_251]
32-17	4451-4454	and	abstract[251]	new[251]	_	_
32-18	4455-4459	TEWL	abstract[251]|quantity	new[251]|giv	coref	34-11
32-19	4460-4461	)	_	_	_	_
32-20	4462-4463	.	_	_	_	_

#Text=This means that the improvements observed in the active area were statistically higher than the improvements observed in the placebo area .
33-1	4464-4468	This	event	giv	coref	34-34
33-2	4469-4474	means	_	_	_	_
33-3	4475-4479	that	_	_	_	_
33-4	4480-4483	the	abstract[254]	new[254]	_	_
33-5	4484-4496	improvements	abstract[254]	new[254]	_	_
33-6	4497-4505	observed	_	_	_	_
33-7	4506-4508	in	_	_	_	_
33-8	4509-4512	the	place[255]	new[255]	coref	33-19[258_255]
33-9	4513-4519	active	place[255]	new[255]	_	_
33-10	4520-4524	area	place[255]	new[255]	_	_
33-11	4525-4529	were	_	_	_	_
33-12	4530-4543	statistically	_	_	_	_
33-13	4544-4550	higher	_	_	_	_
33-14	4551-4555	than	_	_	_	_
33-15	4556-4559	the	abstract[256]	new[256]	_	_
33-16	4560-4572	improvements	abstract[256]	new[256]	_	_
33-17	4573-4581	observed	_	_	_	_
33-18	4582-4584	in	_	_	_	_
33-19	4585-4588	the	place[258]	giv[258]	coref	34-16[266_258]
33-20	4589-4596	placebo	person|place[258]	giv|giv[258]	coref	36-31
33-21	4597-4601	area	place[258]	giv[258]	_	_
33-22	4602-4603	.	_	_	_	_

#Text=Instrumental measurements of skin hydration and transepidermal water loss ( TEWL ) were performed on a selected area ( 9 cm2 ) of the forearms at the baseline and after 4 weeks of treatment .
34-1	4604-4616	Instrumental	abstract[259]	new[259]	_	_
34-2	4617-4629	measurements	abstract[259]	new[259]	_	_
34-3	4630-4632	of	abstract[259]	new[259]	_	_
34-4	4633-4637	skin	abstract[259]|object|substance[261]|abstract[262]	new[259]|giv|giv[261]|giv[262]	coref|coref|coref|coref|coref|coref	35-1[273_261]|36-11|35-1[273_261]|36-11|35-1[273_261]|36-11
34-5	4638-4647	hydration	abstract[259]|substance[261]|abstract[262]	new[259]|giv[261]|giv[262]	_	_
34-6	4648-4651	and	abstract[259]|abstract[262]	new[259]|giv[262]	_	_
34-7	4652-4666	transepidermal	abstract[259]|abstract[262]|abstract[264]	new[259]|giv[262]|giv[264]	_	_
34-8	4667-4672	water	abstract[259]|abstract[262]|substance|abstract[264]	new[259]|giv[262]|giv|giv[264]	_	_
34-9	4673-4677	loss	abstract[259]|abstract[262]|abstract[264]	new[259]|giv[262]|giv[264]	_	_
34-10	4678-4679	(	_	_	_	_
34-11	4680-4684	TEWL	abstract	giv	coref	41-5
34-12	4685-4686	)	_	_	_	_
34-13	4687-4691	were	_	_	_	_
34-14	4692-4701	performed	_	_	_	_
34-15	4702-4704	on	_	_	_	_
34-16	4705-4706	a	place[266]	giv[266]	_	_
34-17	4707-4715	selected	place[266]	giv[266]	_	_
34-18	4716-4720	area	place[266]	giv[266]	_	_
34-19	4721-4722	(	_	_	_	_
34-20	4723-4724	9	quantity[267]	new[267]	_	_
34-21	4725-4728	cm2	quantity[267]	new[267]	_	_
34-22	4729-4730	)	_	_	_	_
34-23	4731-4733	of	_	_	_	_
34-24	4734-4737	the	object[268]	giv[268]	_	_
34-25	4738-4746	forearms	object[268]	giv[268]	_	_
34-26	4747-4749	at	object[268]	giv[268]	_	_
34-27	4750-4753	the	object[268]|abstract[269]	giv[268]|new[269]	_	_
34-28	4754-4762	baseline	object[268]|abstract[269]	giv[268]|new[269]	_	_
34-29	4763-4766	and	_	_	_	_
34-30	4767-4772	after	_	_	_	_
34-31	4773-4774	4	time[270]	giv[270]	coref	37-18[296_270]
34-32	4775-4780	weeks	time[270]	giv[270]	_	_
34-33	4781-4783	of	time[270]	giv[270]	_	_
34-34	4784-4793	treatment	time[270]|event	giv[270]|giv	coref	37-21
34-35	4794-4795	.	_	_	_	_

#Text=Skin Hydration
35-1	4796-4800	Skin	person|abstract[273]	new|giv[273]	coref|coref	36-11[277_273]|36-11[277_273]
35-2	4801-4810	Hydration	abstract[273]	giv[273]	_	_

#Text=A statistically significant increase in the mean basal values of skin hydration was evidenced after 4 weeks of application of both the ceramides and trehalose based ingredient cream and the placebo product ( Table 2 ) .
36-1	4811-4812	A	abstract[274]	new[274]	_	_
36-2	4813-4826	statistically	abstract[274]	new[274]	_	_
36-3	4827-4838	significant	abstract[274]	new[274]	_	_
36-4	4839-4847	increase	abstract[274]	new[274]	_	_
36-5	4848-4850	in	abstract[274]	new[274]	_	_
36-6	4851-4854	the	abstract[274]|abstract[275]	new[274]|giv[275]	_	_
36-7	4855-4859	mean	abstract[274]|abstract[275]	new[274]|giv[275]	_	_
36-8	4860-4865	basal	abstract[274]|abstract[275]	new[274]|giv[275]	_	_
36-9	4866-4872	values	abstract[274]|abstract[275]	new[274]|giv[275]	_	_
36-10	4873-4875	of	abstract[274]|abstract[275]	new[274]|giv[275]	_	_
36-11	4876-4880	skin	abstract[274]|abstract[275]|object|substance[277]	new[274]|giv[275]|giv|giv[277]	coref|coref|coref|coref	40-13|40-13[304_277]|40-13|40-13[304_277]
36-12	4881-4890	hydration	abstract[274]|abstract[275]|substance[277]	new[274]|giv[275]|giv[277]	_	_
36-13	4891-4894	was	_	_	_	_
36-14	4895-4904	evidenced	_	_	_	_
36-15	4905-4910	after	_	_	_	_
36-16	4911-4912	4	time[278]	new[278]	_	_
36-17	4913-4918	weeks	time[278]	new[278]	_	_
36-18	4919-4921	of	time[278]	new[278]	_	_
36-19	4922-4933	application	time[278]|abstract[279]	new[278]|new[279]	_	_
36-20	4934-4936	of	time[278]|abstract[279]	new[278]|new[279]	_	_
36-21	4937-4941	both	time[278]|abstract[279]|substance[280]	new[278]|new[279]|new[280]	coref	37-6[0_280]
36-22	4942-4945	the	time[278]|abstract[279]|substance[280]	new[278]|new[279]|new[280]	_	_
36-23	4946-4955	ceramides	time[278]|abstract[279]|substance[280]	new[278]|new[279]|new[280]	_	_
36-24	4956-4959	and	time[278]|abstract[279]	new[278]|new[279]	_	_
36-25	4960-4969	trehalose	time[278]|abstract[279]|substance	new[278]|new[279]|giv	coref	37-8
36-26	4970-4975	based	time[278]|abstract[279]|substance[283]	new[278]|new[279]|new[283]	coref	37-9[292_283]
36-27	4976-4986	ingredient	time[278]|abstract[279]|substance|substance[283]	new[278]|new[279]|giv|new[283]	coref	37-10
36-28	4987-4992	cream	time[278]|abstract[279]|substance[283]	new[278]|new[279]|new[283]	_	_
36-29	4993-4996	and	time[278]|abstract[279]	new[278]|new[279]	_	_
36-30	4997-5000	the	time[278]|abstract[279]|object[285]	new[278]|new[279]|giv[285]	coref	37-13[295_285]
36-31	5001-5008	placebo	time[278]|abstract[279]|person|object[285]	new[278]|new[279]|giv|giv[285]	coref	37-13
36-32	5009-5016	product	time[278]|abstract[279]|object[285]	new[278]|new[279]|giv[285]	_	_
36-33	5017-5018	(	_	_	_	_
36-34	5019-5024	Table	abstract[286]	new[286]	_	_
36-35	5025-5026	2	abstract[286]	new[286]	_	_
36-36	5027-5028	)	_	_	_	_
36-37	5029-5030	.	_	_	_	_

#Text=A statistically significant difference between ceramides and trehalose based ingredient cream and placebo product was detected after 4 weeks of treatment (
37-1	5031-5032	A	abstract[287]	new[287]	_	_
37-2	5033-5046	statistically	abstract[287]	new[287]	_	_
37-3	5047-5058	significant	abstract[287]	new[287]	_	_
37-4	5059-5069	difference	abstract[287]	new[287]	_	_
37-5	5070-5077	between	abstract[287]	new[287]	_	_
37-6	5078-5087	ceramides	abstract[287]|substance|substance[289]	new[287]|giv|giv[289]	coref|coref	40-6|40-6
37-7	5088-5091	and	abstract[287]|substance[289]	new[287]|giv[289]	_	_
37-8	5092-5101	trehalose	abstract[287]|substance[289]|substance	new[287]|giv[289]|giv	coref	40-4
37-9	5102-5107	based	abstract[287]|substance[289]|substance[292]|substance[293]	new[287]|giv[289]|giv[292]|giv[293]	coref|coref	40-1[299_292]|40-1[299_292]
37-10	5108-5118	ingredient	abstract[287]|substance[289]|substance|substance[292]|substance[293]	new[287]|giv[289]|giv|giv[292]|giv[293]	coref	40-8
37-11	5119-5124	cream	abstract[287]|substance[289]|substance[292]|substance[293]	new[287]|giv[289]|giv[292]|giv[293]	_	_
37-12	5125-5128	and	abstract[287]|substance[289]|substance[293]	new[287]|giv[289]|giv[293]	_	_
37-13	5129-5136	placebo	abstract[287]|substance[289]|substance[293]|person|object[295]	new[287]|giv[289]|giv[293]|giv|giv[295]	coref|coref	40-18|40-18
37-14	5137-5144	product	abstract[287]|substance[289]|substance[293]|object[295]	new[287]|giv[289]|giv[293]|giv[295]	_	_
37-15	5145-5148	was	_	_	_	_
37-16	5149-5157	detected	_	_	_	_
37-17	5158-5163	after	_	_	_	_
37-18	5164-5165	4	time[296]	giv[296]	_	_
37-19	5166-5171	weeks	time[296]	giv[296]	_	_
37-20	5172-5174	of	time[296]	giv[296]	_	_
37-21	5175-5184	treatment	time[296]|event	giv[296]|giv	_	_
37-22	5185-5186	(	_	_	_	_

#Text=Figure 4
38-1	5187-5193	Figure	abstract[298]	new[298]	_	_
38-2	5194-5195	4	abstract[298]	new[298]	_	_

#Text=) .
39-1	5196-5197	)	_	_	_	_
39-2	5198-5199	.	_	_	_	_

#Text=The cream containing trehalose and ceramides based ingredient is able to improve skin hydration if compared to placebo .
40-1	5200-5203	The	substance[299]	giv[299]	_	_
40-2	5204-5209	cream	substance[299]	giv[299]	_	_
40-3	5210-5220	containing	_	_	_	_
40-4	5221-5230	trehalose	substance	giv	_	_
40-5	5231-5234	and	_	_	_	_
40-6	5235-5244	ceramides	substance	giv	_	_
40-7	5245-5250	based	_	_	_	_
40-8	5251-5261	ingredient	substance	giv	_	_
40-9	5262-5264	is	_	_	_	_
40-10	5265-5269	able	_	_	_	_
40-11	5270-5272	to	_	_	_	_
40-12	5273-5280	improve	_	_	_	_
40-13	5281-5285	skin	object|substance[304]	giv|giv[304]	_	_
40-14	5286-5295	hydration	substance[304]	giv[304]	_	_
40-15	5296-5298	if	_	_	_	_
40-16	5299-5307	compared	_	_	_	_
40-17	5308-5310	to	_	_	_	_
40-18	5311-5318	placebo	person	giv	_	_
40-19	5319-5320	.	_	_	_	_

#Text=Transepidermal Water Loss ( TEWL )
41-1	5321-5335	Transepidermal	person[306]	giv[306]	_	_
41-2	5336-5341	Water	person[306]	giv[306]	_	_
41-3	5342-5346	Loss	person[306]	giv[306]	_	_
41-4	5347-5348	(	_	_	_	_
41-5	5349-5353	TEWL	abstract	giv	_	_
41-6	5354-5355	)	_	_	_	_
